Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Mathios, Dimitrios
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. [electronic resource] - Science translational medicine 12 2016 - 370ra180 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1946-6242
10.1126/scitranslmed.aag2942 doi
Animals
Antibodies, Monoclonal--pharmacology
Antibodies, Neoplasm--pharmacology
Antineoplastic Agents--pharmacology
Brain Neoplasms--drug therapy
Carmustine--pharmacology
Cell Line, Tumor
Disease Models, Animal
Disease Progression
Female
Flow Cytometry
Glioblastoma--drug therapy
Glioma--drug therapy
Humans
Immunosuppressive Agents--pharmacology
Immunotherapy
Mice
Mice, Inbred C57BL
Microglia--metabolism
Programmed Cell Death 1 Receptor--immunology
Treatment Outcome
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. [electronic resource] - Science translational medicine 12 2016 - 370ra180 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1946-6242
10.1126/scitranslmed.aag2942 doi
Animals
Antibodies, Monoclonal--pharmacology
Antibodies, Neoplasm--pharmacology
Antineoplastic Agents--pharmacology
Brain Neoplasms--drug therapy
Carmustine--pharmacology
Cell Line, Tumor
Disease Models, Animal
Disease Progression
Female
Flow Cytometry
Glioblastoma--drug therapy
Glioma--drug therapy
Humans
Immunosuppressive Agents--pharmacology
Immunotherapy
Mice
Mice, Inbred C57BL
Microglia--metabolism
Programmed Cell Death 1 Receptor--immunology
Treatment Outcome